valacyclovir / Generic mfg. - LARVOL DELTA

A case report of Kounis syndrome type I triggered by sugammadex administration (Euroanaesthesia 2025) - "1)Case Report: We report a case of Type I KS following the administration of sugammadex, a reversal agent for rocuronium-induced neuromuscular blockade...His medical history included a valacyclovir allergy and a smoking history of 20 cigarettes/day for 15 years but no evidence of coronary artery disease, electrocardiogram (ECG) abnormalities, or exercise intolerance...In this case, rapid diagnosis and therapeutic intervention ensured a favorable outcome. ​"

Case report • Clinical • Acute Coronary Syndrome • Anesthesia • Bladder Cancer • Cardiovascular • Coronary Artery Disease • Dyslipidemia • Hypertension • Hypotension • Immunology • Oncology • Solid Tumor

Retrospective study of antimicrobial prophylaxis and infections in patients with acute myeloid leukemia. (ASCO 2025) - "The most common induction therapies were 7 + 3 (63.5%), azacitidine (11.1%), azacitidine + venetoclax (6.3%), and 7 + 3 + midostaurin (4.8%). 55/63 (87.3%) patients received fungal prophylaxis, usually posaconazole (n = 47)...47/63 (74.6%) patients received viral prophylaxis with acyclovir or valacyclovir... In this single-center retrospective study, fungal and viral prophylaxis were used in most patients, whereas bacterial prophylaxis was rare. Bacterial infections were frequently encountered with a high rate of bacteremia. Aspergillus was the most common fungal pathogen, reinforcing the importance of mold-active fungal prophylaxis."

Retrospective data • Acute Myelogenous Leukemia • Acute Promyelocytic Leukemia • Hematological Disorders • Hematological Malignancies • Infectious Disease • Leukemia • Neutropenia • Novel Coronavirus Disease • Oncology • Pneumonia • Respiratory Diseases

Phase 3, randomized, placebo-controlled clinical trial of CAN-2409+prodrug in combination with standard of care external beam radiation (EBRT) for newly diagnosed localized prostate cancer. (ASCO 2025) - P3 | "CAN-2409 is a replication-defective adenovirus encoding the HSV-tk gene that, when combined with valacyclovir (prodrug), results in immunogenic cell death. In this randomized, double-blind, Phase 3 trial, CAN-2409 significantly reduced the risk of PrCa recurrence or death when added to SoC EBRT+/- ADT. The addition of CAN-2409 was not associated with significant added toxicity. These data represent the first potentially new therapy for patients with intermediate and high risk PrCa in over 20 years."

Clinical • Combination therapy • P3 data • Genito-urinary Cancer • Oncology • Prostate Cancer • Solid Tumor

INCIDENCE AND RISK FACTORS OF HERPES ZOSTER INFECTION IN PEDIATRIC SYSTEMIC LUPUS ERYTHEMATOSUS: A 16 YEAR STUDY (EULAR 2025) - "The median Systemic Lupus Erythematosus Disease Activity Index (SLEDAI) at herpes zoster diagnosis was 4 (IQR = 0 – 12), 16.39% had recurrent HZI, 11.48% had superimposed bacterial infection, and more than two-thirds were treated with the anti-viral acyclovir or valacyclovir (88.52%). The prevalence and incidence of HZI in cSLE is 15.72% and 38.40 per 100 person-years, respectively. Risk factors identified for HZI among cSLE were lymphopenia, lupus nephritis, and immunosuppressive agents. In particular, IV cyclophosphamide, azathioprine, and glucocorticoid dose of ≥5mg increased the risk for development of HZI by 1.61, 2.07, 10.20 times, respectively."

Clinical • Glomerulonephritis • Herpes Zoster • Immunology • Infectious Disease • Inflammatory Arthritis • Lupus • Lupus Nephritis • Nephrology • Pediatrics • Rheumatology • Systemic Lupus Erythematosus • Varicella Zoster

Adenovirus Vasculitis with Necrotising Retinitis and Schisis-Associated Macular Edema (SAME): A Rare Primary Manifestation of HIV-Related Immunodeficiency. (PubMed, Ocul Immunol Inflamm) - "Initial treatment involved topical corticosteroids, intravitreal ganciclovir, and systemic valganciclovir. Due to disease progression, therapy was subsequently escalated to high-dose valacyclovir (2 g TID) with intravitreal ganciclovir and later intravenous cidofovir was introduced...Adenoviral necrotizing retinitis remains an underrecognized entity, particularly in immunocompromised patients. This case underscores the importance of PCR testing for HAdV in atypical necrotizing retinitis and highlights the need for a combined treatment approach, including systemic and intravitreal antiviral therapy."

Journal • Cardiovascular • Genetic Disorders • Hematological Disorders • Human Immunodeficiency Virus • Infectious Disease • Macular Edema • Ocular Inflammation • Ophthalmology • Retinal Disorders • Vasculitis • CD4

Valacyclovir-induced neurotoxicity and nephrotoxicity in an elderly patient with a history of nephrectomy: a case report. (PubMed, BMC Nephrol) - "This case report demonstrates a rare case of acute kidney injury due to an exaggerated response to valacyclovir-induced crystal nephropathy, presenting in tandem with valacyclovir-induced neurotoxicity, which has only been described in three case reports. This case highlights the importance of careful history and physical exam to facilitate a more accurate and timely diagnosis, especially in patients with a history of nephrectomy."

Journal • Acute Kidney Injury • Cardiovascular • Chronic Kidney Disease • Diabetes • Dyslipidemia • Hematological Disorders • Herpes Simplex • Herpes Zoster • Hypertension • Infectious Disease • Metabolic Disorders • Nephrology • Pain • Renal Calculi • Renal Disease • Thrombocytopenic Purpura • Type 2 Diabetes Mellitus • Varicella Zoster

Valacyclovir in Pain Management of Acute Apical Abscesses (clinicaltrials.gov) - P2 | N=60 | Recruiting | Sponsor: University of California, San Francisco | N=250 ➔ 60 | Trial completion date: Nov 2024 ➔ Dec 2025 | Trial primary completion date: May 2024 ➔ Dec 2025

Enrollment change • Trial completion date • Trial primary completion date • Pain

Synthesis, characterization and antiviral efficacy of Valacyclovir loaded polymeric nanoparticles against wild-type Herpes Simplex Virus type 2. (PubMed, Biomed Mater) - "The results demonstrated that the valacyclovir-loaded nanoparticles exhibited a 1.2-1.3-fold increase in antiviral efficacy compared to the free drug. This study thus presents a novel nanotechnology-based treatment approach for HSV-2, offering enhanced antiviral effectiveness over traditional treatments.&#xD."

Journal • Herpes Simplex

Case Report: Donor-derived herpes simplex virus type 1 hepatitis in a kidney transplant recipient with fatal outcome. (PubMed, Front Transplant) - "The HSV-1 infection in the recipient was initially overlooked and misattributed to a probable mycophenolate mofetil-induced etiology, which led to a delay in initiating antiviral therapy. As a result of this case, our transplant center promptly revised its screening and prophylactic antiviral treatment protocols. All kidney transplant recipients who are herpes simplex virus (HSV) antibody-negative now receive valaciclovir until the donor's HSV DNA PCR status is confirmed to be negative."

Journal • Hepatology • Herpes Simplex • Infectious Disease • Inflammation • Liver Failure • Solid Organ Transplantation • Transplantation

An Atypical Presentation of Post-herpetic Neuralgia and Bell's Palsy in a Diabetic Patient: A Case Report. (PubMed, Cureus) - "Beginning with an initial treatment of gabapentin, significant relief was ultimately achieved with valacyclovir, emphasizing the importance of early and targeted intervention in PHN management. This case underscores the complexities of diagnosing PHN, especially in the presence of comorbidities, and highlights the need for further research to refine treatment strategies for this debilitating condition."

Journal • CNS Disorders • Dermatology • Diabetes • Herpes Zoster • Infectious Disease • Metabolic Disorders • Neuralgia • Pain • Pruritus • Type 2 Diabetes Mellitus • Varicella Zoster

The critical role of early diagnosis, multidisciplinary management, and social determinants in severe eczema herpeticum: a case study of a 24-year-old man (SID 2025) - "A 24-year-old male, with a history of atopic dermatitis previously well controlled with dupilumab, presented to the emergency department with a four-week history of painful, pruritic skin vesicles and erosions, which had progressed to crusted plaques affecting his face, neck, chest, arms, and thighs...Eczema herpeticum was suspected and he was started on empiric acyclovir 5mg/kg IV every 8 hours...Due to periocular impetiginization, ophthalmology was consulted, and mupirocin ointment was applied twice daily to the face...Within five days, the patient showed clinical improvement, was transitioned to oral valacyclovir, and connected to multidisciplinary outpatient services for continuity after discharge...Disclaimer: This research was supported (in whole or in part) by HCA Healthcare and/or an HCA Healthcare affiliated entity. The views expressed in this publication represent those of the author(s) and do not necessarily represent the official views of HCA Healthcare or..."

Case study • Clinical • Atopic Dermatitis • Dermatitis • Dermatology • Herpes Simplex • Immunology • Ophthalmology • Pain

Valacyclovir Toxicity in ESRD Unmasked by Thorough History in Intubated Patient (ATS 2025) - "An EEG confirmed epileptiform activity, and she was treated with Keppra and Vimpat...Her ICU stay was prolonged by failed spontaneous breathing trials (SBTs), and she showed minimal response to modafinil on Day 14...Neurotoxicity arises from the accumulation of acyclovir's active metabolite, which, without adequate renal clearance, crosses the blood-brain barrier and leads to encephalopathic symptoms, as seen in this patient... The patient's condition improved following discontinuation of valacyclovir and ongoing dialysis. This case emphasized the critical role of careful medication management in ESRD patients, particularly for drugs like valacyclovir that have neurotoxic potential."

Clinical • Anesthesia • Cardiovascular • Chronic Kidney Disease • CNS Disorders • Congestive Heart Failure • Epilepsy • Heart Failure • Herpes Zoster • Infectious Disease • Movement Disorders • Nephrology • Psychiatry • Renal Disease • Varicella Zoster

Atypical Presentation of Hematopoietic Stem Cell Transplantation Associated Thrombotic Microangiopathy (ATS 2025) - "His post-transplant course had been complicated by severe graft-versus-host-disease of the skin and gastrointestinal tract treated with tacrolimus, steroids, sandostatin, and photopheresis. His medications included tacrolimus, sirolimus, prednisone, valacyclovir, posaconazole, meropenem, and linezolid...Primary intervention should be withdrawal of calcineurin inhibitors, and although frequently used, plasma exchange results may vary. Our patient presented with DAH likely as a manifestation of his TMA."

Acute Myelogenous Leukemia • Bone Marrow Transplantation • Cough • Dermatology • Gastrointestinal Disorder • Graft versus Host Disease • Hematological Disorders • Hematological Malignancies • Immunology • Leukemia • Oncology • Pulmonary Disease • Respiratory Diseases • Thrombosis • Transplantation • HP

Respiratory Complications in Multiple Myeloma: A Case of Pneumonitis Induced by Daratumumab (ATS 2025) - "Her medication regimen included fluoxetine, pravastatin, morphine, trazodone, pantoprazole, valacyclovir, and levothyroxine...The patient was initially treated with IV doxycycline and cefepime for atypical pneumonia, and she also received IV solumedrol for pneumonitis with significant improvement in oxygen requirement...Acute interstitial pneumonitis is a rapidly progressive interstitial lung disease with an unclear etiology. While various medications, particularly antineoplastic agents, have been associated with DIIP, this case underscores the need to recognize rare but serious pulmonary side effects associated with immunotherapy, especially in patients with underlying malignancies."

Clinical • Bronchiectasis • Cough • Hematological Malignancies • Infectious Disease • Inflammation • Interstitial Lung Disease • Multiple Myeloma • Oncology • Pain • Pneumonia • Tuberculosis

ATYPICAL PRESENTATION OF HERPES ZOSTER ENCEPHALITIS IN AN IMMUNOCOMPETENT ADOLESCENT (ESPID 2025) - "Diagnosed with herpes zoster (HZ) encephalitis, he was treated with intravenous acyclovir for 8 days and discharged on oral valaciclovir. Here, a VZV-proven dermatomal rash and VZV-positive cerebrospinal fluid confirmed the diagnosis. Additionally, the pseudotumor cerebri-like presentation broadens the diagnostic challenges of paediatric HZ encephalitis."

Herpes Zoster • Human Immunodeficiency Virus • Infectious Disease • Varicella Zoster

VALACYCLOVIR IN PREGNANCY FOR THE PREVENTION OF CONGENITAL CYTOMEGALOVIRUS: A SINGLE-CENTER EXPERIENCE (ESPID 2025) - "Conclusions/Learning Points Our data demonstrate the efficacy of VCV in reducing the rate of cCMV at the time of amniocentesis,with a good safety profile. Furthermore, the treatment was associated with a reduction in symptomatic cCMV infection at birth."

Clinical • Cytomegalovirus Infection • Infectious Disease

TEMPORAL TRENDS IN THE CLINICAL PRESENTATION, MANAGEMENT AND OUTCOMES OF CHILDREN WITH CONGENITAL CYTOMEGALOVIRUS INFECTION IN EUROPE (ESPID 2025) - "Treatment Maternal treatment with immunoglobulins was more frequent in P1(11.4% vs 7.6%; p=0.020), while valaciclovir treatment was more frequent in P2(0.4% vs 10.7%; p<0.001)...Isolated ganciclovir and valganciclovir treatment were more frequent in P1(7.3% vs 2.7%; p<0.001), and P2(43.9% vs 78.3%; p<0.001), respectively, while combined treatment was more common in P1(48.8% vs 19.0%; p<0.001)...In recent years, these children are more frequently diagnosed during the fetal period, less likely to be born with symptoms, more likely to receive oral valganciclovir, and show improved outcomes. In children born after 2017, the prevalence of SNHL, motor impairment, and epilepsy at 24 months of age is lower."

Clinical • Cytomegalovirus Infection • Infectious Disease

ORAL VALACYCLOVIR MATERNAL TREATMENT DURING PREGNANCY AND LONG-TERM SEQUALAE OF CONGENITAL CMV (CCMV) INFECTED NEONATES (ESPID 2025) - "This study addresses the need for maternal screening early in pregnancy and timely administration of maternal valacyclovir. Trimester of maternal infection Total (n=745) Valacyclovir treatment (n=16) First 87 (11.7%) 11 (12.6%) Second 30 (4.0%) 1 (3.3%) Third 38 (5.1%) 1 (2.6%) Unknown 590 (79.2%) 3 (0.5%)"

Cytomegalovirus Infection

A case of chancroid in a Spanish man returning from an endemic area. (PubMed, Int J STD AIDS) - "Thus, a seven-day course of Valaciclovir 500 mg twice daily orally was prescribed...Ceftriaxone 1 g STAT intramuscular was administered with subsequent improvement...Its prevalence in STI clinics has varied from 0% to 0.5%. It must be suspected, especially in travellers to endemic countries in the first days of their return due to its short incubation period."

Journal • Herpes Simplex • Herpes Zoster • Infectious Disease • Pain • Varicella Zoster

A Study of the Safety, Tolerability and Prelinminary Efficacy of BD111 in Herpes Simplex Virus Type I Stromal Keratitis (clinicaltrials.gov) - P1 | N=16 | Active, not recruiting | Sponsor: Shanghai BDgene Co., Ltd. | Recruiting ➔ Active, not recruiting | Trial completion date: Sep 2025 ➔ Mar 2026

Enrollment closed • Trial completion date • Herpes Simplex • Keratitis • Ocular Inflammation • Ophthalmology

INFECTIOUS COMPLICATIONS DURING INDUCTION CHEMOTHERAPY IN YOUNG ADULTS WITH ACUTE MYELOID LEUKEMIA: A RETROSPECTIVE ANALYSIS OF CLINICAL OUTCOMES AND THERAPEUTIC STRATEGIES (EHA 2025) - "Regarding viral infections, 2 cases of SARS-CoV-2 infection were documented.The most frequently used antibiotic therapy class during FEs was beta-lactams, with piperacillin-tazobactam (46.8%) and ceftazidime (4.3%). Carbapenems were used in 38.3%.Among antifungal agents, amphotericin B was used in 12.8%, fluconazole in 27.7%, and voriconazole in 19.1%. For antiviral treatment, valaciclovir was used in 10.6%.Of the 36 patients, 91.6% (n=33) underwent bone marrow evaluation after the induction phase, while 3 patients died before being evaluated... Empirical antibiotic therapy has played a major role in reducing mortality from chemotherapy-induced infections. However, the increasing emergence of MRB strains presents a significant therapeutic challenge. Our findings align closely with national and international data."

Clinical data • Retrospective data • Acute Myelogenous Leukemia • Hematological Disorders • Hematological Malignancies • Infectious Disease • Leukemia • Novel Coronavirus Disease • Oncology • Respiratory Diseases

[Translated article] The need for prolonged antiviral use to prevent recurrences of herpes simplex virus ocular disease: A systematic review. (PubMed, Farm Hosp) - "Prolonged use of antivirals protects from ocular, non-ocular recurrences and stromal keratitis safely. The effects on visual acuity are not known."

Journal • Herpes Simplex • Keratitis • Ocular Inflammation • Ophthalmology

Efficacy and Safety of Antivirals in Lactating Women with Herpesviridae Infections: A Systematic Review. (PubMed, Viruses) - "Results suggest that antiviral agents, particularly acyclovir and valacyclovir, are generally safe for breastfeeding mothers, with minimal infant exposure and low risk of adverse effects. However, the virologic benefits appear modest, and most studies focused on HIV co-infected populations, limiting generalizability to lactating women without HIV. In conclusion, while current evidence supports the use of specific antivirals during lactation, there is a critical need for further research to address existing knowledge gaps and optimize treatment strategies for both mothers and infants."

Journal • Review • Cytomegalovirus Infection • Epstein-Barr Virus Infections • Herpes Simplex • Herpes Zoster • Human Immunodeficiency Virus • Infectious Disease • Varicella Zoster

Neonatal Phase 1 Valacyclovir Study (clinicaltrials.gov) - P1 | N=16 | Recruiting | Sponsor: National Institute of Allergy and Infectious Diseases (NIAID) | Trial completion date: Mar 2025 ➔ Sep 2025 | Trial primary completion date: Mar 2025 ➔ Aug 2025

Trial completion date • Trial primary completion date • Herpes Simplex • Infectious Disease

Description of Nephrotoxic Medication Exposure among Critically Ill Children who develop Acute Kidney Injury. (PAS 2025) - "Review of NTMx data indicated exposure to one or more specific NTMx groups (vancomycin, intravenous contrast, antivirals, NSAIDs, calcineurin inhibitors, and piperacillin/tazobactam) between 3 days prior and 7 days after NINJA flag. Overall, 72 patients were included in this review (table 1). Vancomycin exposure occurred in 78% of patients who developed NTMx-AKI. Antiviral medications (acyclovir, ganciclovir, valganciclovir, and valacyclovir) were significantly associated with development of severe AKI (stage 1 = 26% vs severe = 55%, p=0.02)."

Clinical • Acute Kidney Injury • Nephrology • Pediatrics • Renal Disease